Objective-Our aim was to identify the role of the homeostatic chemokines CCL19 and CCL21 and their common receptor CCR7 in atherogenesis and to study the relationships between CCL19, CCL21, and CCR7 gene variants and coronary artery disease in a Chinese Han population. Approach and Results-Immunohistochemical analysis of samples with atherosclerosis of various stages showed increased CCL19, CCL21, and CCR7 expression in atherosclerotic coronary plaques compared with nonatherosclerotic controls. Expression levels increased in positive correlation with coronary lesion stage. Cell adhesion assays confirmed that CCL19 promoted monocyte adhesion, which was induced by CCR7, to human umbilical vein endothelial cells, an effect partially antagonized by atorvastatin. After the human umbilical vein endothelial cells were treated with CCR7-neutralizing antibody, both CCL19-and CCL21-induced monocyte to human umbilical vein endothelial cell migration and CCL19induced monocyte to human umbilical vein endothelial cell adhesion were abolished. The associations between genetic variants of CCL19, CCL21, CCR7, and coronary artery disease in a Chinese Han population were determined by matrixassisted laser desorption/ionization time-of-flight mass spectrometry. The following single nucleotide polymorphisms were associated with coronary artery disease: CCL19 rs2227302, CCL21 rs2812377, and CCR7 rs588019. Individuals with the CCL19 rs2227302 T allele or CCL21 rs2812377 G allele had higher plasma CCL19 levels than those with C/C genotype and higher CCL21 levels than those with T/T genotype in both case and control subjects. Conclusion-CCL19/CCL21-CCR7 is a novel homeostatic chemokine system that modulates human monocyte adhesion and migration, promoting atherogenesis. It is associated with coronary artery disease risk in Chinese Han individuals. These data suggest that the CCL19/CCL21-CCR7 axis plays an important role in atherosclerosis progression. (Arterioscler Thromb Vasc Biol. 2014;34:1933-1941 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
C hronic inflammation plays an important role in the pathogenesis of atherosclerosis, which is a major underlying cause of coronary artery disease (CAD). 1 Leukocyte recruitment is a key event in vascular inflammation, and it produces local inflammatory signaling molecules and results in a feed-forward cycle of atherogenesis and systemic inflammation. Recent studies have suggested that the recruitment of inflammatory cells into the vessel wall is coordinated by the production of chemokines and their corresponding G-proteincoupled receptors. 2 The upregulation of circulatory and vascular chemokines has emerged as an important mechanism in leukocyte recruitment, early vascular inflammation, and atherogenesis.
Most chemokines have been linked to inflammation in the arterial wall, whereas the homeostatic chemokines CCL19 and CCL21 and their corresponding receptor CCR7 have been associated with the modulation of inflammatory responses in lymphoid and nonlymphoid tissues, 3, 4 including atherosclerotic lesions, 5 indicating that they may play a pathogenic role in atherosclerosis development. Elevated levels of circulating CCL19 and CCL21 have recently been found in stable angina patients, whereas particularly high levels were observed in unstable angina patients. 5 In contrast, a recent report showed that the expression of CCL19/CCL21/CCR7 was significantly downregulated in human atherosclerotic carotid plaques compared with nonatherosclerotic controls. 6 Divergent results might stem from the different models used: Damås et al 5 used the renal artery as control, whereas the aorta served as the study control for Nickel et al. 6 Together, these findings suggest the complexity of the CCR7 signaling way. It is crucial to clarify the roles of CCL19, CCL21, and CCR7 in human atherogenesis to gain better understanding of the disease.
To study the relationships between CCL19, CCL21, and CCR7 and atherosclerosis and to eliminate tissue heterogeneity as a confounder, the tissues chosen for the current study were normal and atherosclerotic human coronary arteries. We investigated the roles of CCL19, CCL21, and CCR7 in promoting monocyte adhesion and migration. We furthermore determined if genetic variations in the CCL19/CCL21/CCR7 might contribute to CAD in Chinese Han population.
Materials and Methods
Materials and Methods are available in the online Data Supplement.
Results

Increased CCL19/CCL21/CCR7 Expression in Human Atherosclerotic Lesions
To determine if CCL19/CCL21/CCR7 expression levels were changed in human atherosclerotic plaques, we compared expression levels in human coronary atherosclerotic plaques with controls. Immunostaining of coronary plaques showed that the CCL19/CCL21/CCR7 system was expressed at all stages of atherosclerosis development ranging from diffuse intimal thickening, via fibrous cap atheroma, to complicated plaque lesions. Expression levels increased gradually in line with the development of atherosclerosis. Immunostaining of CCL19/CCL21/CCR7 in normal coronary tissues was significantly weaker than those in atherosclerotic coronary tissues ( Figure 1 ). CCL19/CCL21/CCR7 levels were also increased in human carotid plaques compared with normal controls ( Figure I in the online-only Data Supplement).
The expression of CCL19, CCL21, and CCR7 in endothelial cells (ECs), smooth muscle cells, T cells, and macrophages was also identified by immunostaining of serial sections (Figure 2 ; Figures II and III in the online-only Data Supplement). No CD3 + T cells or CD68 + macrophages were found in normal coronary vessels, and CCL19/CCL21/CCR7 expression was low ( Figure 3 ). CD3 + T cells and CD68 + macrophages were found in atherosclerotic coronary vessels, and CCL19/CCL21/CCR7 expression was high. There were more T cells and macrophages within atherosclerotic plaque than in normal coronary tissues; T cells and macrophages exhibited CCL19/CCL21/CCR7 expression ( Figure 2 ; Figure 
Effects of Lipopolysaccharide and Atorvastatin on CCL19/CCL21/CCR7 in Human Umbilical Vein Endothelial Cells
Lipopolysaccharide stimulates inflammation; statins may confer some of their cardiovascular benefits by modulating the inflammatory process in atherosclerosis. 7 We, therefore, examined the ability of atorvastatin to modulate levels of CCL19/CCL21/CCR7 in human umbilical vein endothelial cells (HUVECs). To induce the inflammatory response, HUVECs were stimulated with lipopolysaccharide for 2 hours (5 ng/mL). After lipopolysaccharide stimulus, CCL19/ CCL21 expression in supernatant and CCR7 in HUVEC lysates markedly increased. Atorvastatin induced a significant decrease in CCL19/CCL21/CCR7 production from lipopolysaccharide-activated HUVECs ( Figure 4A ).
Effect of CCL19/CCL21/CCR7 and Atorvastatin on the Migration and Adhesion of Monocytes to HUVECs
Previous researches have reported that CCR7 expression levels were extremely low in monocytes themselves. 8 However, CCR7 expression was markedly upregulated during monocytic transition to macrophages. 5 To determine the CCR7 expression in monocytes used specifically in our experimental settings, CCR7 was determined by flow cytometry in CD14 + monocytes. Our results were consistent with previously reported results. CCR7 was detected in ≈2.24% monocytes ( Figure IV in the online-only Data Supplement).
To examine whether CCL19/CCL21 induction increased monocyte adhesion and migration, we performed monocyte HUVEC adhesion and monocyte migration assays under static conditions.
First, we pretreated ECs with the blocking anti-CCR7 antibody to block endothelium-expressed CCR7, then determined the adhesion and migration effect of monocyte to ECs. CCL19 treatment significantly altered the adhesion ( Figure 4B and 4D) and migration ( Figure 4C and 4E) of monocytes to HUVECs, whereas CCL21 only increased the migration of monocytes to HUVECs ( Figure 4C and 4E). The addition of CCR7neutralizing antibody abolished both CCL19-and CCL21induced monocyte migration and CCL19-induced monocyte adhesion. The treatment of cultured HUVECs with atorvastatin also significantly reduced monocyte adhesion ( Figure 4B and 4D) and migration ( Figure 4C and 4E).
Association Between CCL19/CCL21/ CCR7 Polymorphisms and CAD
The findings that CCL19/CCL21/CCR7 expression was increased in atherosclerotic lesions and that CCL19/CCL21/ CCR7 affected monocyte migration and adhesion suggested that CCL19/CCL21/CCR7 might play an important role in the development of atherosclerosis. We, therefore, investigated the influence of CCL19/CCL21/CCR7 gene variations on CAD. The genotype distributions of CCL19/CCL21/CCR7 polymorphisms in both groups were in Hardy-Weinberg equilibrium in both Chinese Han populations. CCL19 rs2227302, CCL21 rs2812377, and CCR7 rs588019 were associated with CAD in the first population (Northern Hospital). No CD3 + T cells or CD68 + macrophages were found in normal coronary vessels, and CCL19/CCL21/CCR7 expression was low (A-E). CD3 + T cells and CD68 + macrophages were found in atherosclerotic coronary vessels, and CCL19/CCL21/CCR7 expression was high (F-J). Scale bar, 100 μm.
Carriers of the rs2227302 T allele (C/T plus T/T genotypes), rs2812377 G allele (T/G plus G/G genotypes), and rs588019 A allele
carriers (A/G plus A/A genotypes)
were all significantly overrepresented among patients with CAD relative to control subjects (11.4% versus 6.9%; P<0.001; 60.6% versus 55.1%; P=0.002; 9.4% versus 6.3%; P=0.001, respectively). These associations remained significant (P=0.0017, 0.004, and 0.002, respectively) after adjusting for classic cardiovascular risk factors, including age, sex, body mass index, smoking, hypercholesterolemia, hypertension, and diabetes mellitus ( Table 1 ). There were no significant differences in the allele frequencies or genotype distributions of the other 9 single nucleotide polymorphisms (SNPs; CCL19 rs3136658, CCL19 rs3176817, CCL21 rs11574915, CCL21 rs10972201, CCR7 rs3136685, CCR7 rs2023906, and CCR7 rs2290065) between patients with CAD and control subjects. alone; CCL21, HUVECs incubated with CCL21 alone; anti-CCR7, HUVECs pretreated with CCR7-neutralizing antibody before LPS/ CCL19/CCL21 incubation; and atorvastatin, HUVECs pretreated with atorvastatin before LPS/CCL19/CCL21 incubation. A, To induce the inflammatory response, HUVECs were stimulated with LPS for 2 h. After LPS stimulus, CCL19/CCL21/CCR7 expression was markedly increased. Atorvastatin induced a significant decrease in CCL19/CCL21/CCR7 production from LPS-activated HUVECs. CCL19 and CCL21 present in HUVEC cultured supernatant were determined by ELISA, and CCR7 expression in HUVEC lysate was determined by Western blot. Data represent mean±SD of samples from 3 separate experiments. **P<0.01, significantly different from control; ##P<0.01, significantly different from LPS treatment. B, HUVECs were stimulated with LPS/CCL19/CCL21 for 2 h before addition of monocytes in adhesion assays. Human monocytes labeled with 15 μl/mL calcein for 30 min, and then washed twice before plating at 1×10 5 cells per well of HUVECs. Cells (monocytes and HUVECs) were incubated together at 37°C for 2 h and washed 3× with PBS. Positively stained monocyte cells were counted by fluorescent microscopy with 5 random fields per well per condition (magnification, ×4). Experiments were performed in triplicate on 3 different days. C, Monocytic migration assays were performed by transwell system, allowing monocytes to migrate through an 8-μm (pore size) polycarbonate membrane. HUVECs seeded into the lower chamber were stimulated with LPS/ CCL19/CCL21 for 2 h before addition of monocytes in migration assays. Monocytes were seeded into the upper chamber. The cells (monocytes and HUVECs) were incubated together at 37°C for 12 h. The filters were removed after 12 h. Migration was assessed by counting the number of cells that adhered to the lower side of the filter membrane. Migrated cells were fixed and stained with Giemsa dye. Cell counts were performed by counting 5 random fields per filter using an imaging system under a light microscope (magnification, ×10). D, Adhesion of monocytes to HUVECs was determined under indicated conditions. E, Migration of monocytes was determined under indicated conditions. Data represent mean±SD from 5 separate fields in each sample from 3 independent experiments. **P<0.01, significantly different from control; ##P<0.01, significantly different from LPS treatment alone; ∆∆P<0.01, significantly different from CCL19 treatment alone; ▲▲P<0.01, significantly different from CCL21 treatment alone. Differences between groups were analyzed by 1-way ANOVA. Scale bar, 20 μm. The associations between the CCL19/CCL21/CCR7 gene variants and CAD were replicated in the second independent case-control samples (Southern Hospital; Table 1 ). After adjusting for classic cardiovascular risk factors, the distributions of carriers of the rs2227302 T allele (C/T plus T/T genotypes), rs2812377 G allele (T/G plus G/G genotypes), and rs588019 A allele carriers (A/G plus A/A genotypes) were all higher in patients with CAD than in control subjects (11.4% versus 7.0%; P=0.005; 61.4% versus 54.3%; P=0.009; 8.9% versus 5.9%; P=0.03, respectively). These results confirmed the association between CCL19/CCL21/CCR7 gene variants and CAD in the Chinese Han population.
Plasma CCL19 and CCL21 Levels in Subsets of Subjects
We performed a case-control study of plasma CCL19 and CCL21 levels to investigate if there was an association between CCL19 and CCL21 expression and SNPs. CCL19 and CCL21 plasma levels were significantly higher in patients with CAD compared with control subjects (499.7±22.1 versus 879.6±44.3; P<0.001; 81.1±15.7 versus 134.7±19.1; P<0.001, respectively). Further analyses showed that the disease susceptible genotypes rs2227302 C/T and T/T were associated with higher plasma CCL19 production than the C/C genotype in both patients and controls (197.6±111.1 versus 121.2±42.0 versus 70.5±30.7; 126.4±28.0 versus 78.6±22.5 versus 44.4±19.7), whereas plasma levels of CCL21 in rs2812377 G/G homozygotes and T/G heterozygotes were significantly higher than in T/T homozygotes in both groups (1072.9±382.0 versus 814.5±251.3 versus 595.5±170.5; 603.1±109.5 versus 526.6±94.2 versus 444.9±94.8; Figure 5 ).
Discussion
Atherosclerosis is a chronic inflammatory disease in which the progression because of plaque destabilization is mediated by chemokines. 1, 9 Expression levels of CCL19 and CCL21 and their receptor CCR7 were previously reported to be enhanced within human atherosclerotic carotid lesions. 5 Our current study demonstrated increased CCL19/CCL21/CCR7 expression in atherosclerotic coronary tissues, which was associated with the progression of atherosclerotic lesions. We also demonstrated that CCL19/CCL21/CCR7 directly promoted atherogenesis assessed by monocyte adhesion and migration in vitro. Moreover, CCL19 rs2227302, CCL21 rs2812377, and CCR7 rs588019 were significantly associated with CAD in Chinese Han population; rs2227302 T allele carriers and rs2812377 G allele carriers had significantly higher plasma CCL19 and CCL21 levels, respectively.
In recent studies, both CCR7 and its ligands, CCL19 and CCL21, were present in mouse and human atherosclerotic plaques. However, there remains controversy regarding the role of CCR7 in atherosclerosis. Luchtefeld et al 10 experiment, we used normal and atherosclerotic coronary arteries from human beings to elucidate this issue. Given the fact that conclusions drawn from experiments on rodent species might be totally different in human beings, we optimistically thought that our results based on human tissue might be more convincing to the scientific community.
In this study, we determined that normal coronary artery adventitia can express CCL19/CCL21/CCR7. The arterial wall can be divided into 3 layers: the intima, media, and adventitia. Several studies reveal that the adventitial cell population includes monocytes, macrophages, and resident fibroblasts together with myofibroblasts. These cells are associated with local production of proinflammatory mediators (cytokines and growth factors) as well as connective tissue production. 13 Moreover, we demonstrated the expression of CCL19/CCL21/ CCR7 in normal coronary artery adventitia (Figure 1) . At least 2 possibilities exist. First, the inflammatory cells in the adventitia might express CCL19/CCL21/CCR7. Second, previous studies have shown the expression of chemokines and their receptors in adipocytes in peripheral tissue. 14, 15 Adipocytes also express CCL19/CCL21/CCR7. Both the arterial media and the hyperplastic intima initiate the expression of CCL19/ CCL21/CCR7 in the atherosclerotic coronary artery, which may be associated with phenotypic transformation of vascular smooth muscle cells. In the normal coronary artery, smooth muscle cells are primarily the contractive phenotype, with low expression levels of CCL19/CCL21/CCR7. During atherosclerosis, smooth muscle cells convert to the secretory phenotype, and high levels of CCL19/CCL21/CCR7 expression are detected in the arterial media and hyperplastic intima ( Figure 2 ; Figure II in the online-only Data Supplement).
We also demonstrated CCL19/CCL21/CCR7 expression in human coronary artery ECs for the first time ( Figure 2 ; Figure II in the online-only Data Supplement). Because EC dysfunction is the hallmark of atherosclerotic lesion initiation and progression during the early stage of atherosclerosis, it is essential to determine the relationship between increased CCL19/CCL21/CCR7 expression and atherogenesis. As the cells lining the entire inner surface of blood vessels, vascular ECs are perpetually exposed to a wide variety of blood-borne plasma stimulants. Monocytic recruitment by adhesion to ECs, their consequent transendothelial migration, and their retention in a complex milieu of proatherosclerotic stimuli promote monocyte transformation into macrophages and macrophagederived foam cells. 16, 17 Persistent bacterial infections resulting in a chronic inflammatory condition have clearly been associated with increased incidence of atherosclerosis, 18 and chronic inflammation triggered by metabolic mediators such as cholesterol and ceramide have been reported to promote the development of atherosclerosis. 19, 20 Serum lipopolysaccharide levels, a common bacterially derived product, are associated with a greater risk of atherosclerosis in humans. 21 Furthermore, chemokines are not typically expressed in unstimulated cells, tissues, or cell lines, but are rapidly induced (usually <1-2 hours poststimulation) in response to either endogenous or exogenous stimuli. Typically, agents enhancing inflammation (eg, lipopolysaccharide, interleukin-1, tumor necrosis factor, injurious stimuli, and infectious agents) or immune activation (eg, lectins, antigenic stimulation, mitogens, immunoglobulin E/ antigen, and phorbol esters) also promote chemokine production. In our study, we primarily focused on the role of inflammation during atheroprogression. Lipopolysaccharide was thus selected as the stimulus to induce EC injury and inflammatory response. In our study, lipopolysaccharide induced an inflammatory and dysfunctional state in HUVECs, increased CCL19-CCR7 production, and enhanced monocyte adhesion.
Using blocking antibodies, we demonstrated that monocyte adherence to ECs was CCL19-CCR7-dependent. To our knowledge, this is the first report demonstrating that CCR7 on HUVECs is required for monocyte-HUVEC adhesive effect.
In addition to decreasing lipid levels, statins also exert anti-inflammatory effects in vascular cells. Only aggressive statin therapy has been shown to induce changes in plasma CCL19/CCL21/CCR7 levels. 5 However, the effects of statins on CCL19/CCL21/CCR7 expression in HUVECs remained unknown. In this study, we demonstrated that clinically achievable concentrations of atorvastatin suppressed CCL19/CCL21/CCR7 expression and inhibited CCL19/ CCL21-induced monocyte adhesion and migration. Overall, these results suggested that statins may suppress the atherogenic effects of CCL19 and CCL21, the effect of statins inhibiting inflammation, and expression of various chemokines and receptors in HUVECs. 22, 23 Statin may reduce CCL19 and CCL21 plasma levels in patients with CAD. 5 Together, this information might aid in developing strategies controlling occurrence and development of atherosclerosis. However, the mechanism underlying statin inhibition of CCL19/CCL21 expression in HUVECs requires further elucidation.
The current study also provided the first comprehensive analysis of the association between SNPs in the CCL19, CCL21, and CCR7 genes and the risk of CAD in the Chinese Han population. After adjusting for various risk factors, the CCL19 rs2227302, CCL21 rs2812377, and CCR7 rs588019 polymorphisms were shown to be associated with CAD.
The rs2227302 polymorphism was located at the 3′ untranslated region of the CCL19 gene, and the variant T allele significantly increased the risk of CAD. In addition, ELISA analyses showed that the disease susceptible genotypes C/T and T/T were associated with higher CCL19 production in the plasma compared with the C/C genotype in both groups of subjects. It was possible that SNPs at the 3′ untranslated region may affect gene expression at the post-transcriptional level by interfering with protein binding, polyadenylation, or microRNA binding. 24, 25 Using the Website http://snpinfo. niehs.nih.gov/snpinfo/snpfunc.htm, the rs2227302 T allele was predicted to disrupt the binding sites for 3 microRNAs (hsa-miR-339-5p, hsa-miR-146b-3p, and hsa-miR-484), which may be responsible for increased CCL19 expression. SNP rs2812377 of CCL21 was located in the promoter regions of CCL21. TFSEARCH (http://www.cbrc.jp/research/ db/TFSEARCH.html) predicted that rs2812377 was located in the core of activator protein-1 binding motif, suggesting that the existence of the polymorphism may affect transcription factor binding to the promoter region. Previous studies had implicated the common inflammatory transcription factor activator protein-1 in the initiation and progression of endothelial dysfunction and atherogenesis. 26 Meanwhile, we found that the G allele of CCL21 rs2812377 polymorphism increased the risk of CAD and was associated with higher plasma levels of CCL21. This suggested that the rs2812377 G allele in the CCL21 promoter may enhance the binding affinity of activator protein-1 to this region, which may promote the expression of CCL21. SNP rs588019 of CCR7 was located in the intron regions of the CCR7 gene. SNP rs588019, although intronic, could itself be causal. An increasing piece of evidence indicates that intronic genetic variations can have deleterious implications for gene splicing. 27 Indeed, recent evidence from many laboratories indicated that intronic variants can be functional and, as a result, were often the cause of human diseases. 28, 29 Therefore, the disease-associated rs588019 in CCR7 may be functional in terms of splicing regulation, or alternatively they may monitor functional elements within the gene associated with CAD risk. Additional functional analyses of this SNP are needed to elucidate the underlying mechanism.
Our study showed that the CCL19 polymorphism rs2227302 T allele, CCL21 gene rs2812377 G allele, and CCR7 rs588019 A allele may be genetic risk factors for CAD in the northern Chinese Han population.
This study had several limitations. First, the sample size may not have been large enough to allow the conclusions to be extended to the entire Chinese Han population. Second, the multiple analyses performed that the possibility that our findings were because of chance could not be excluded. In addition, the study cohort was specifically Chinese, and the results may not be applicable to other ethnic groups. Data from other populations are, therefore, needed to confirm these preliminary observations. Third, the mechanisms underlying the associations between CCL19 rs2227302, CCL21 rs2812377, and CCR7 rs588019 polymorphisms and CAD risk required further investigation. Fourth, regarding the difference between CCL21 and CCL19, our results demonstrated that the stimulation of HUVECs with CCL19 induces monocyte adhesion and migration, whereas stimulation with CCL21 only induced migration but not adhesion. The precise mechanisms responsible for this difference cannot be addressed in the current study. However, this difference might be related to the different receptor internalization after CCL19 and CCL21 binding. Specifically, previous study reported that binding of CCL19 causes 80% of CCR7 internalization, whereas binding with CCL21 only caused 20% CCR7 internalization. Different levels of receptor internalization not only caused different amount of surface receptor that may have caused different intracellular signaling, but also caused different adaptor protein recruitment and receptor recycles. 30 In conclusion, the results of this study suggest that increased CCL19/CCL21/CCR7 expression may be a risk factor for atherosclerosis, and reducing CCL19/CCL21/CCR7 levels in the human body may represent a novel therapeutic strategy. Figure 5 . Plasma CCL19 and CCL21 levels in patients with coronary artery disease (CAD) and controls. A, Plasma CCL19 levels in patients and controls with different CCL19 rs2227302 genotypes. CCL19 levels were greater in patients with CAD compared with control subjects (P<0.001), and T allele carriers (C/T and T/T genotypes) exhibited increased CCL19 levels compared with subjects with C/C genotype in both CAD and control groups. B, Plasma CCL21 levels in patients and controls with different CCL21 rs2812377 genotypes. CCL21 levels were greater in patients with CAD compared with control subjects (P<0.001), and subjects with G allele carriers (T/G and G/G genotypes) exhibited greater CCL21 levels than T/T genotypes in both CAD and control groups. Differences between groups were analyzed by 1-way ANOVA. *P<0.05; **P<0.01; ***P<0.001.
